Teva Pharmaceutical has appointed R. Ananthanarayanan (Ananth) CEO of its active pharmaceutical ingredient (API) business. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva’s U.S. headquarters in Parsippany, NJ.
 
Ananth joins Teva with over 34 years of experience leading global API businesses in external sales, internal operations, and in contract development and manufacturing operations. He will lead Teva api through its transformation to a standalone business, which plays a critical part in Teva’s Pivot to Growth strategy announced in May 2023. Having led the former Teva api and biologics operations organization at Teva from 2014 to 2018, Ananth has a deep understanding of Teva’s API business.
 
Prior to joining Teva, Ananth served as CEO of a portfolio company of a global leading private equity firm, and a leading CDMO for large scale production of active ingredients for agro, electronic chemicals, specialty chemicals, and intermediates for agro, pharma, dyes and pigments. Prior to this, he served as CEO of Strides Pharma Science, a global generic pharmaceutical company, and as chief operating officer at Cipla.
 
Richard Francis, Teva’s president and CEO said, “I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company as we continue to progress on our plan for turning Teva api into a standalone business. We’re confident that this strategy will result in a more focused end-to-end operation, and I am confident that Ananth’s extensive knowledge of both Teva and the industry landscape will be an invaluable asset to drive growth, maximize current and potential revenue streams, and better serve customers and patients.”